Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.

Lassman AB, Rossi MR, Raizer JJ, Abrey LE, Lieberman FS, Grefe CN, Lamborn K, Pao W, Shih AH, Kuhn JG, Wilson R, Nowak NJ, Cowell JK, DeAngelis LM, Wen P, Gilbert MR, Chang S, Yung WA, Prados M, Holland EC.

Clin Cancer Res. 2005 Nov 1;11(21):7841-50. Erratum in: Clin Cancer Res. 2006 Jan 1;12(1):322. Razier, Jeffrey R [corrected to Raizer, Jeffrey J].

2.

Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway.

Rosell R, Taron M, Reguart N, Isla D, Moran T.

Clin Cancer Res. 2006 Dec 15;12(24):7222-31. Review.

3.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938
4.

Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.

Jänne PA.

Lung Cancer. 2008 Jun;60 Suppl 2:S3-9. doi: 10.1016/S0169-5002(08)70099-0. Review.

PMID:
18513582
5.
6.

Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.

Ahmed SM, Salgia R.

Respirology. 2006 Nov;11(6):687-92. Review.

PMID:
17052295
7.

Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments.

Brandes AA, Franceschi E, Tosoni A, Hegi ME, Stupp R.

Clin Cancer Res. 2008 Feb 15;14(4):957-60. doi: 10.1158/1078-0432.CCR-07-1810. Review.

9.

Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Di Maio M, Gridelli C, Normanno N, Perrone F, Ciardiello F.

J Cell Physiol. 2005 Dec;205(3):355-63. Review.

PMID:
15895392
10.
11.
12.

The epidermal growth factor receptor in malignant gliomas: pathogenesis and therapeutic implications.

Nakamura JL.

Expert Opin Ther Targets. 2007 Apr;11(4):463-72. Review.

PMID:
17373877
13.

Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.

Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A, Wirtz CR.

Cancer Treat Rev. 2006 Apr;32(2):74-89. Epub 2006 Feb 20. Review.

PMID:
16488082
14.

Erlotinib in glioblastoma: lost in translation?

Karpel-Massler G, Westhoff MA, Kast RE, Wirtz CR, Halatsch ME.

Anticancer Agents Med Chem. 2011 Oct;11(8):748-55. Review.

PMID:
21707495
15.

Erlotinib: early clinical development in brain cancer.

Addeo R, Zappavigna S, Parlato C, Caraglia M.

Expert Opin Investig Drugs. 2014 Jul;23(7):1027-37. doi: 10.1517/13543784.2014.918950. Epub 2014 May 16. Review.

PMID:
24836441
16.

Small-molecule inhibitors of the human epidermal receptor family.

Carter CA, Kelly RJ, Giaccone G.

Expert Opin Investig Drugs. 2009 Dec;18(12):1829-42. doi: 10.1517/13543780903373343. Review.

PMID:
19938898
17.

Role of chemotherapy on brain metastasis.

Lee SH.

Prog Neurol Surg. 2012;25:110-4. doi: 10.1159/000331183. Epub 2012 Jan 6. Review.

PMID:
22236672
18.

Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition.

Yano S, Kondo K, Yamaguchi M, Richmond G, Hutchison M, Wakeling A, Averbuch S, Wadsworth P.

Anticancer Res. 2003 Sep-Oct;23(5A):3639-50. Review.

PMID:
14666659
19.

Drug combinations enhancing the antineoplastic effects of erlotinib in high-grade glioma.

Karpel-Massler G, Wirtz CR, Halatsch ME.

Recent Pat Anticancer Drug Discov. 2011 Sep;6(3):384-94. doi: 10.2174/157489211796957748. Review.

PMID:
21612575
20.

Diagnosis and therapy of oral squamous cell carcinoma.

Konkimalla VB, Suhas VL, Chandra NR, Gebhart E, Efferth T.

Expert Rev Anticancer Ther. 2007 Mar;7(3):317-29. Review.

PMID:
17338652

Supplemental Content

Support Center